rhophilin Rho GTPase binding protein 2Genealiases: P76RBE · RHOBP
Q-omics provides the consensus-scored RHPN2 profile across patient tissues and cancer cell-line models. RHPN2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHPN2 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, RHPN2 RNA expression shows 19,581 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where RHPN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHPN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHPN2 survival associations across molecular data types. RHPN2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHPN2 RNA expression–survival associations across cancer types. High RHPN2 expression shows unfavorable associations in ACC, OV, LGG, LUAD and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHPN2 RNA expression.
This table summarizes RHPN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RHPN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHPN2 shows lower tumor expression in THCA and higher tumor expression in KIRP, LUAD, KIRC, BLCA and UCEC. The KIRP box plot shows higher RHPN2 RNA expression in tumor versus normal tissue (log2 FC = +1.148, t-test p < 0.001).
This table shows molecular features associated with RHPN2 in patient tissues and cancer cell lines. In patient samples, RHPN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHPN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
